Wednesday, 22 Jan 2020

You are here

High Dose Statins Increase Odds of Osteoporosis

It is unknown if inhibiting cholesterol synthesis (with statins) might influence sex-hormone production and therefore, the risk of osteoporosis.  A new study shows that, in statin-treated individuals, the development of osteoporosis is statin dose-dependent. 

This Austrian, claims based study (2006 to 2007) examined the association between statin therapy and OP risk.

The found that in the general population, statin use was associated with a 3 fold higher rate of osteoporosis (OR: 3.62, 95% CI 3.55 to 3.69, p<0.01).

Osteoporosis was significantly lower with low-dose (< 10 mg) statin treatment (e.g., lovastatin [OR: 0.39], pravastatin [OR: 0.68], simvastatin [OR: 0.70] and rosuvastatin [OR: 0.69]; p<0.01).

In contrast, higher doses significantly increased the odds of OP (> 40 mg simvastatin [OR: 1.64]; >20 mg atorvastatin [OR: 1.78]; >20 mg rosuvastatin [OR: 2.04].

It appears that the risk of OP is largely dose-dependent as regards statin use.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Should We Screen Younger Postmenopausal Women for Osteoporosis?

Do postmenopausal women, under age 65 years, need a baseline BMD testing? A JAMA Insights review suggests that the absolute risk of fracture is low in this group and that USPSTF guidelines should be considered - that we should be screening women younger than 65 years who are at increased risk of osteoporosis and we should be using a formal risk assessment tool to identify candidates for bone density testing.

Genicular Artery Embolization to Treat Osteoarthritis Knee Pain

A study from the Journal of Vascular and Interventional Radiology has shown that  knee pain secondary to osteoarthritis (OA) may be effectively treated by selective vascular interruption (embolization) showing efficacy and safety in a small pilot trial. 

ACR-Arthritis Foundation Treatment Guidelines for Osteoarthritis

Today, the American College of Rheumatology (ACR), in partnership with the Arthritis Foundation (AF), released the 2019 ACR/AF Guideline for the Management of Osteoarthritis of the Hand, Hip and Knee. The ACR periodically updates guidelines to reflect any advances in management added to the literature since the last publication, which in this case was 2012.

Short-term Benefit with Prednisolone in Hand Osteoarthritis

Lancet reports that prednisolone 10 mg daily for 6 weeks can effectively control the pain of hand osteoarthritis (OA), according to results from the Hand Osteoarthritis Prednisolone Efficacy (HOPE) study. This was a double-blind, randomized, placebo-controlled trial aimed to assess the short-term effects of prednisolone in painful hand OA and synovial inflammation. Patients were required to have hand OA and signs of inflammation in their distal and proximal interphalangeal (DIP/PIP) joints and > 4 DIP/PIP osteoarthritic nodes and at least one DIP/PIP joint with soft swelling/erythema or evidence of synovitis on power Doppler ultrasound. The primary endpoint was finger pain.

Physical Activity Lowers Fracture Risk in Post-Menopausal Women

An analysis from the Women’s Health Initiative study shows that postmenopausal women who participate in vigorous physical activity have a statistically lower risk of total and site-specific fractures